Blood online
Home About Blood Authors Subscriptions Permission Advertising Public Access contact us
 

 
Advanced
Current Issue
First Edition
Archives
Submit to Blood
Search
American Society of Hematology
Meeting Abstracts
Email Alerts
 Blood, 15 June 2008, Vol. 111, No. 12, pp. 5446-5456.
Prepublished online as a Blood First Edition Paper on January 23, 2008; DOI 10.1182/blood-2007-06-093906.

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Supplemental Appendix
Right arrow All Versions of this Article:
blood-2007-06-093906v1
111/12/5446    most recent
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Right arrow Rights and Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via CrossRef
Google Scholar
Right arrow Articles by Hallek, M.
Right arrow Articles by Kipps, T. J.
PubMed
Right arrow PubMed Citation
Right arrow Articles by Hallek, M.
Right arrow Articles by Kipps, T. J.
Related Collections
Right arrow Neoplasia
Right arrow Free Research Articles
Right arrow Review Articles
Right arrow Clinical Trials and Observations
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us   Add to Digg   Add to Reddit   Add to Technorati  
What's this?

arrow to previous article Previous Article  |  Table of Contents  |  Next Article next article arrow

REVIEW ARTICLE

Guidelines for the diagnosis and treatment of chronic lymphocytic leukemia: a report from the International Workshop on Chronic Lymphocytic Leukemia updating the National Cancer Institute–Working Group 1996 guidelines

Michael Hallek1, Bruce D. Cheson2, Daniel Catovsky3, Federico Caligaris-Cappio4, Guillaume Dighiero5, Hartmut Döhner6, Peter Hillmen7, Michael J. Keating8, Emili Montserrat9, Kanti R. Rai10, and Thomas J. Kipps11

1 Klinik I für Innere Medizin, Universität zu Köln, Köln, Germany; 2 Georgetown University Hospital, Lombardi Cancer Center, Washington, DC; 3 Institute of Cancer Research, London, United Kingdom; 4 Universita Vita-Salute Istituto di Ricovero e Cura a Carattere Scientifico (IRCSS) San Raffaele, Milano, Italy; 5 Institute Pasteur, Montevideo, Uruguay; 6 University of Ulm, Ulm, Germany; 7 Pinderfields Hospital, Wakefield, United Kingdom; 8 Department of Leukemia, University of Texas, M. D. Anderson Cancer Center, Houston; 9 Hospital Clinic, Barcelona, Spain; 10 Division of Hematology/Oncology, Long Island Jewish Medical Center, New Hyde Park, NY; and 11 Rebecca and John Moores Cancer Center, University of California–San Diego, La Jolla

Standardized criteria for diagnosis and response assessment are needed to interpret and compare clinical trials and for approval of new therapeutic agents by regulatory agencies. Therefore, a National Cancer Institute–sponsored Working Group (NCI-WG) on chronic lymphocytic leukemia (CLL) published guidelines for the design and conduct of clinical trials for patients with CLL in 1988, which were updated in 1996. During the past decade, considerable progress has been achieved in defining new prognostic markers, diagnostic parameters, and treatment options. This prompted the International Workshop on Chronic Lymphocytic Leukemia (IWCLL) to provide updated recommendations for the management of CLL in clinical trials and general practice.


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati    What's this?


This article has been cited by other articles:


Home page
 BloodHome page
L. Z. Rassenti, S. Jain, M. J. Keating, W. G. Wierda, M. R. Grever, J. C. Byrd, N. E. Kay, J. R. Brown, J. G. Gribben, D. S. Neuberg, et al.
Relative value of ZAP-70, CD38, and immunoglobulin mutation status in predicting aggressive disease in chronic lymphocytic leukemia
Blood, September 1, 2008; 112(5): 1923 - 1930.
[Abstract] [Full Text] [PDF]

Home page
 BloodHome page
C. S. Tam, S. O'Brien, W. Wierda, H. Kantarjian, S. Wen, K.-A. Do, D. A. Thomas, J. Cortes, S. Lerner, and M. J. Keating
Long-term results of the fludarabine, cyclophosphamide, and rituximab regimen as initial therapy of chronic lymphocytic leukemia
Blood, August 15, 2008; 112(4): 975 - 980.
[Abstract] [Full Text] [PDF]

Home page
 BloodHome page
R. Proto-Siqueira, R. A. Panepucci, F. P. Careta, A. Lee, A. Clear, K. Morris, C. Owen, E. G. Rizzatti, W. A. Silva Jr, R. P. Falcao, et al.
SAGE analysis demonstrates increased expression of TOSO contributing to Fas-mediated resistance in CLL
Blood, July 15, 2008; 112(2): 394 - 397.
[Abstract] [Full Text] [PDF]


click for free articles
home about blood authors subscriptions permissions advertising public access contact us
  Copyright © 2008 by American Society of Hematology         Online ISSN: 1528-0020